Name: Why the customer has opted for a human challenge model to support its vaccine development.
Uploaded: 2023-06-28T06:27:02.940932+00:00
Duration: 449 s
Channel: Vox Markets
Description: Why the customer has opted for a human challenge model to support its vaccine development.

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/928/005928/video_RbmAv08.mp4#t=194

Vox Markets

Why the customer has opted for a human challenge model to support its vaccine development.

30 Discussing the brand-new human challenge model, the world’s first for the Human metapneumovirus (hMPV) to be developed in conjunction with a large US biotech.

The importance of developing treatments for hMPV, for which no vaccine or antiviral currently exists.

Insights into the customer, a long-term partner of hVivo, and how hVivo will be using the model for other customers.

The timescales and process involved in bringing the hMPV human challenge model into use.

Further validation of the power of human challenge models in expediting rapid drug development.

Vox speak to hVivo’s Mo Khan about the company’s latest human challenge model, to be developed in conjunction with a customer to develop the world’s first treatments for the Human metapneumovirus.

0:30 Discussing the brand-new human challenge model, the world’s first for the Human metapneumovirus (hMPV) to be developed in conjunction with a large US biotech.
1:51 The importance of developing treatments for hMPV, for which no vaccine or antiviral currently exists.
3:14 Why the customer has opted for a human challenge model to support its vaccine development. 
4:11 Insights into the customer, a long-term partner of hVivo, and how hVivo will be using the model for other customers.
4:57 The timescales and process involved in bringing the hMPV human challengemodel into use.
6:08 Further validation of the power of human challenge models in expediting rapid drug development

Vox speak to hVivo’s Mo Khan about the company’s latest human challenge model, to be developed in conjunction with a customer to develop the world’s first treatments for the Human metapneumovirus.0:30 Discussing the brand-new human challenge model, the world’s first for the Human metapneumovirus (hMPV) to be developed in conjunction with a large US biotech. 1:51 The importance of developing treatments for hMPV, for which no vaccine or antiviral currently exists. 3:14 Why the customer has opted for a human challenge model to support its vaccine development. 4:11 Insights into the customer, a long-term partner of hVivo, and how hVivo will be using the model for other customers. 4:57 The timescales and process involved in bringing the hMPV human challengemodel into use. 6:08 Further validation of the power of human challenge models in expediting rapid drug development

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/928/005928/video_RbmAv08.mp4